Risk-stratified sequential treatment with ibrutinib and rituximab (IR) and IR-CHOP for de-novo post-transplant lymphoproliferative disorder: results of the tidal trial
Sridhar Chaganti, Shanna Maycock, Graham Mcilroy, Waleed A Iqbal, John Mason, Edward Kanfer, Shireen Kassam, Kate Cwynarski, David Wrench, Arvind K. Arumainathan, Christopher P Fox, Rod Johnson, Pam Mckay, Shankara Paneesha, Clare J Rowntree, Constantine-george Balotis, Graham P. Collins, Andrew Davies, Josh Wright, Keith WheatleyTobias F Menne
Research output: Contribution to journal › Abstract
Fingerprint
Dive into the research topics of 'Risk-stratified sequential treatment with ibrutinib and rituximab (IR) and IR-CHOP for de-novo post-transplant lymphoproliferative disorder: results of the tidal trial'. Together they form a unique fingerprint.